Professor Law's team has pioneered the use of human myoblasts in anti-aging cosmetology. In Cell Transplants Singapore Pte Ltd (CTS) and in Cell Transplants China Guangzhou Ltd (CTCG), a team of professional cell culturists (Fig.1) produce billions of pure myoblasts according to GMP and ISO 9001 guidelines (Fig.2).
Myoblasts are spindle-shaped cells much smaller than the polygonal skin fibroblasts (Fig.3). When seeded onto the skin, they develop into a strong, brighter and smoother skin covering that obliterates wrinkles, blemishes and age-spots (Fig.4). When injected into the muscle under the skin, they augment the shape (Fig.5), size ( Fig.6), consistency and strength of the injected muscle.
A new product VEGF-Ang1-Myoblasts provides growth of capillaries and muscle fibers (Fig.7B) to treat male impotency, skinny / bony / weak vulva and baldness.
Professor Law holds two world patents for cosmetic enhancement; one for subcutaneous injection and one for supracutaneous ‘plating'. These patents govern the use of the myoblasts in controlling the size, shape, consistency, texture, tone, color and strength of the face, forehead, eyes, ears, nose, mouth lips, chin, jaw, neck, shoulders, arms, hands, chest, breasts, back, buttock, legs, penis and vulva.
The World's First Myoblast Study of Type II Diabetic Patients
a report by
PeterK Law, PhD, Danlin Min Law, MD, Lu Ping, MD, Guo Jie, MD, Lu Ying, MD, Xue Yan Feng, MD and Li Xun, MD
Cell Transplants Asia Limited and Chinese Association of Medicinal Biotechnology, Southern Center of Biologic Diagnosis and Therapy, China
Introduction
Type II diabetes, also called non-insulin-dependent diabetes mellitus (NIDDM), is characterized by high blood glucose resulting from the genetic defect of the GLUT4 genome. The latter is manifested in the diminished glucose uptake into skeletal muscles. In normal human beings, insulin combines with insulin receptors to change the membrane conformation of skeletal muscle fibers, allowing blood glucose to move down its concentration gradient into the fibers for metabolism. A disorder called ‘insulin resistance’ exists in Type II diabetic patients in which normal or even elevated levels of plasma insulin would not elicit normal glucose uptake into the muscle fibers. This article hypothesizes that these diabetic fibers exhibit less insulin receptors, or that these receptors exhibit abnormal molecular conformation, or both. Considering that highly metabolic muscle fibers constitute more than 50% of the human body by volume and weight, failure of blood glucose to gain entry would undoubtedly lead to high blood glucose and result in various organ failures sequentially. This is not the only defect, but it is likely the primary and significant one.
A potential genetic treatment of the disease involves myoblast transfer therapy (MTT) which is a platform technology of cell transplantation, genome therapy and tissue engineering.1,2 It consists of culturing immature muscle cells called myoblasts, derived originally from a 2g skeletal muscle biopsy from a healthy, young, male donor, and implanting them into the major muscle groups of the upper and lower extremities of the diabetic patients. The myoblasts exhibit natural cell fusion, and transfer their nuclei carrying the normal human genome into the host skeletal muscle fibers to effect genetic repair. Others fuse among themselves to form new myofibers that exhibit normal insulin receptors of donor origin. Through both mechanisms, new insulin receptors of donor origin that are genetically normal, will be produced in the skeletal myofibers of the host.
The survival, development, and functioning of the implanted allogeneic myoblasts have previously been demonstrated in studies involving about 240 muscular dystrophy subjects and two chronically myocardial infracted heart subjects with 100% safety and substantial efficacy results.3,4 Immunorejection was minimized using two months of cyclosporine following MTT. In addition, over 120 ischemic heart patients have received autologous myoblasts in their hearts in 10 countries. Mortality rate has been less than 10% traversing the last four years, with efficacy data being collected in Phase II clinical trials in Europe. Reported here are the world’s first genetic transplants of two Type II diabetic patients using allogeneic myoblasts.
World's
First Allograft Injection of Human Myoblasts into the Human
Heart
Memphis , TN , January 23, 2003 . On Friday, January 17, 2003 , Cell Transplants International, LLC, (CTI) in collaboration with the Russian Academy of Medical Sciences, completed the world's first allograft injection of human myoblasts into the human heart at the Bakoulev Center in Moscow , Russia . Two patients ages 63 and 49 received 1.1 and 1.2 billion myoblasts respectively. The first transplant began at 11:00 A.M. , and the last transplant was completed at 3:00 P.M. Each procedure lasted approximately ten minutes and was performed open-chest after coronary artery bypass grafting. Before the transplants, all two patients were suffering from angina, myocardial infarction, and shortness of breath. Post-surgery, the patients were in stable condition with no reports of arrhythmia. Six days post-surgery, the patients are continuing to do well and are improving each day. Additional post-surgery analysis will be conducted and the data will be accumulated and published for peer review.
Myoblasts are immature skeletal muscle cells carrying a full complement of normal genes. When transplanted, the cells repair and replace degenerating cells in the defective heart muscle. Because allogenic myoblasts are derived from third-party donors, the patients were administered cyclosporine orally as an immunosuppressant five days prior to transplantation. It is hoped that these myoblasts will repopulate the diseased hearts with live cells in addition to adding some regenerative capacity.
The myoblasts were supplied by CTI through its subsidiary Cell Transplants Singapore Pte. Ltd. (CTS), which has a cGMP facility in the Singapore Science Park . CTS was granted ISO 9000 Certification in November 2002.
Last year, global expenditure in cardiovascular diseases topped 280 billion USD. Less than 5000 donor hearts were available for heart transplants, today's most viable solution for heart failure. With healthcare costs increasing at such a rapid rate and limited availability of donor hearts, this transfer of allogenic myoblasts promises to reduce costs and provide potential treatment to the hundreds of millions of heart attack patients worldwide.
Academician Leo A. Bockeria, M.D., the Chairman of the Bakoulev Scientific Center for Cardiovascular Surgery, was the surgeon responsible for the injections. Academician Bockeria was pleased with the initial results, and he is eager to move forward with the transplantation of the next nine patients included in this study.
Peter K. Law, Ph.D., CTI's Chairman and CEO, pioneered the Myoblast Transfer Technology and holds world patents for its applications. Professor Law was in Moscow as a co-principal investigator during the cardiac procedure. Encouraged by the early results, Professor Law said, "While we are still in the preliminary stages of monitoring the safety and efficacy of this procedure, we are very excited to see that the patients are stable with no arrhythmia. This study, which is the first of its kind in the world, shows tremendous potential to help heart patients worldwide."
About CTI
Cell Transplants International is a Memphis-based company that specializes in using myoblast transplantation as a platform for gene and cell therapy. Formed in 1997, CTI is developing this myoblast transfer technology as a treatment for muscular dystrophy, heart disease, and Type II diabetes.
World's First
Allograft Injection of Human Myoblasts into Human
Heart
* Procedure performed on 2 patients
in collaboration with Russian Academy of Medical
Sciences in Moscow, Russia
